{"brief_title": "A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3", "brief_summary": "To evaluate the effect of ranitidine on immunologic indicators in asymptomatic HIV-1 infected patients with CD4 counts of 400-700 cells/mm3.", "detailed_description": "Patients are randomized to receive either ranitidine or matching placebo bid for 16 weeks, with follow-up every 4 weeks through week 20.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Ranitidine hydrochloride", "criteria": "Inclusion Criteria Patients must have: - Asymptomatic HIV-1 infection. - CD4 count of 400-700 cells/mm3. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Significant illness. - Acute illness at randomization. - Hemodialysis. Prior Medication: Excluded: - Antiretroviral use within 60 days prior to study entry.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00002106.xml"}